These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 27924679)

  • 1. Effect of vitamin D supplementation as adjunctive therapy to methylphenidate on ADHD symptoms: A randomized, double blind, placebo-controlled trial.
    Mohammadpour N; Jazayeri S; Tehrani-Doost M; Djalali M; Hosseini M; Effatpanah M; Davari-Ashtiani R; Karami E
    Nutr Neurosci; 2018 Apr; 21(3):202-209. PubMed ID: 27924679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study.
    Jafarinia M; Mohammadi MR; Modabbernia A; Ashrafi M; Khajavi D; Tabrizi M; Yadegari N; Akhondzadeh S
    Hum Psychopharmacol; 2012 Jul; 27(4):411-8. PubMed ID: 22806822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of vitamin D treatment in children with attention-deficit hyperactivity disorder.
    Dehbokri N; Noorazar G; Ghaffari A; Mehdizadeh G; Sarbakhsh P; Ghaffary S
    World J Pediatr; 2019 Feb; 15(1):78-84. PubMed ID: 30456564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of Vitamin D Supplementation on Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Gan J; Galer P; Ma D; Chen C; Xiong T
    J Child Adolesc Psychopharmacol; 2019 Nov; 29(9):670-687. PubMed ID: 31368773
    [No Abstract]   [Full Text] [Related]  

  • 5. Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial.
    Mohammadi MR; Kazemi MR; Zia E; Rezazadeh SA; Tabrizi M; Akhondzadeh S
    Hum Psychopharmacol; 2010 Nov; 25(7-8):560-5. PubMed ID: 21312290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
    Pliszka SR; Wilens TE; Bostrom S; Arnold VK; Marraffino A; Cutler AJ; López FA; DeSousa NJ; Sallee FR; Incledon B; Newcorn JH
    J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder.
    Findling RL; Bukstein OG; Melmed RD; López FA; Sallee FR; Arnold LE; Pratt RD
    J Clin Psychiatry; 2008 Jan; 69(1):149-59. PubMed ID: 18312050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371].
    Akhondzadeh S; Mohammadi MR; Khademi M
    BMC Psychiatry; 2004 Apr; 4():9. PubMed ID: 15070418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed-Dose Trial.
    Findling RL; Adler LA; Spencer TJ; Goldman R; Hopkins SC; Koblan KS; Kent J; Hsu J; Loebel A
    J Child Adolesc Psychopharmacol; 2019 Mar; 29(2):80-89. PubMed ID: 30694697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial.
    Salehi B; Imani R; Mohammadi MR; Fallah J; Mohammadi M; Ghanizadeh A; Tasviechi AA; Vossoughi A; Rezazadeh SA; Akhondzadeh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):76-80. PubMed ID: 19815048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of tipepidine as adjunctive therapy in children with attention-deficit/hyperactivity disorder: Randomized, double-blind, placebo-controlled clinical trial.
    Dehbozorghi S; Bagheri S; Moradi K; Shokraee K; Mohammadi MR; Akhondzadeh S
    Psychiatry Clin Neurosci; 2019 Nov; 73(11):690-696. PubMed ID: 31294924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crocus sativus L. Versus Methylphenidate in Treatment of Children with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Pilot Study.
    Baziar S; Aqamolaei A; Khadem E; Mortazavi SH; Naderi S; Sahebolzamani E; Mortezaei A; Jalilevand S; Mohammadi MR; Shahmirzadi M; Akhondzadeh S
    J Child Adolesc Psychopharmacol; 2019 Apr; 29(3):205-212. PubMed ID: 30741567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial.
    Cohen-Yavin I; Yoran-Hegesh R; Strous RD; Kotler M; Weizman A; Spivak B
    Clin Neuropharmacol; 2009; 32(4):179-82. PubMed ID: 19644227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. l-Carnosine as Adjunctive Therapy in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Ghajar A; Aghajan-Nashtaei F; Afarideh M; Mohammadi MR; Akhondzadeh S
    J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):331-338. PubMed ID: 29469593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
    Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders.
    Ghuman JK; Aman MG; Lecavalier L; Riddle MA; Gelenberg A; Wright R; Rice S; Ghuman HS; Fort C
    J Child Adolesc Psychopharmacol; 2009 Aug; 19(4):329-39. PubMed ID: 19702485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.
    Kaplan S; Heiligenstein J; West S; Busner J; Harder D; Dittmann R; Casat C; Wernicke JF
    J Atten Disord; 2004 Oct; 8(2):45-52. PubMed ID: 15801334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
    Weiss M; Hechtman L; Turgay A; Jain U; Quinn D; Ahmed TS; Yates T; Reiz JL; Donnelly GA; Harsanyi Z; Darke AC
    J Child Adolesc Psychopharmacol; 2007 Oct; 17(5):675-88. PubMed ID: 17979587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buspirone versus methylphenidate in the treatment of children with attention- deficit/ hyperactivity disorder: randomized double-blind study.
    Mohammadi MR; Hafezi P; Galeiha A; Hajiaghaee R; Akhondzadeh S
    Acta Med Iran; 2012; 50(11):723-8. PubMed ID: 23292622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.